New inhaled drug tested for lung disease – first step in humans
NCT ID NCT06992661
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 22 times
Summary
This early-stage study tests a single inhaled dose of RJ026 in 42 healthy volunteers and 42 people with interstitial lung disease (ILD), a condition that causes lung scarring. The goal is to measure how the drug moves through the body and check for safety, not to treat the disease. Participants receive one of three inhaled doses or an oral version, with blood and lung fluid samples taken over 24 hours.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.